Influenza A virus (H5N8) hemagglutinin (H5N8 HA)

The Influenza A virus (H5N8) hemagglutinin (HA) is a critical surface glycoprotein that facilitates viral entry into host cells by binding to sialic acid receptors and mediating membrane fusion [1][2]. In the context of inactivated whole-virus particles, the HA antigen is presented in its native trimeric conformation, which is essential for eliciting a robust and protective humoral immune response [3]. This target is a primary focus for vaccine development against Highly Pathogenic Avian Influenza (HPAI), as H5N8 has demonstrated significant mortality in avian populations and the potential for zoonotic transmission to humans [4][5]. Neutralizing antibodies induced by vaccines or administered as therapeutics typically target the globular head region to block receptor binding or the conserved stem region to prevent the pH-dependent fusion process [6]. Because the HA protein is subject to frequent antigenic drift, continuous surveillance and the development of candidate vaccine viruses are necessary to ensure therapeutic efficacy [3]. Current pharmacological strategies include the use of fusion inhibitors like Umifenovir and the development of broadly neutralizing monoclonal antibodies that provide cross-protection against multiple influenza subtypes [1][6]. Citations: [1] https://pubmed.ncbi.nlm.nih.gov/25817475/ [2] https://www.uniprot.org/uniprotkb/P03452/entry [3] https://www.who.int/publications/m/item/antigenic-and-genetic-characteristics-of-zoonotic-influenza-viruses-and-development-of-candidate-vaccine-viruses-for-pandemic-preparedness-february-2021 [4] https://www.cdc.gov/flu/avianflu/h5n8-virus.htm [5] https://pubmed.ncbi.nlm.nih.gov/33631105/ [6] https://www.nature.com/articles/nature17414

Other names

H5 hemagglutininHA1/HA2 glycoproteinInfluenza A virus H5N8 surface antigenHemagglutinin protein

Vaccines containing this antigen induce neutralizing antibodies that bind to the HA head or stem regions, preventing viral attachment to sialic acid receptors or blocking the conformational change required for membrane fusion [1][3]. Small molecule inhibitors like Umifenovir directly bind to the HA protein to prevent the structural transition necessary for viral-host membrane fusion [1].